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INTRODUCTION
Endometrial cancer is the most common gynecological malig-
nancy, with approximately 14,000 new cases and 2,200 related
deaths occurring every year in Japan [Japanese Ministry of Health,
Labour and Welfare ; Matsuda et al, 2012]. In 2008, the 1998 In-
ternational Federation of Gynecology and Obstetrics (FIGO)
criteria were revised such that stage IA includes disease that in-
volves the endometrium and/or with50% myometrial invasion
and stage IB includes disease with50% myometrial invasion.
Based on the new definitions, retroperitoneal lymph node me-
tastasis is a critical prognostic factor for patients with endometrial
carcinoma [Creasman, 1989 ; Pecorelli, 2009]. Thus, the National
Comprehensive Cancer Network’s Clinical Practice Guidelines in
Oncology recommend pelvic lymph node and para-aortic lymph
node dissection, rather than nodal sampling, for patients with en-
dometrial cancer [National Comprehensive Cancer Network].
Many studies have reported the value of lymphadenectomy when
treating patients with endometrial cancer, although it is unclear
whether all patients will benefit from undergoing this surgery.
Therefore, we retrospectively reviewed the clinical records and
histopathological factors (e.g., grade, myometrial invasion, and
lymph-vascular space invasion [LVSI]) of patients with endometrial
cancer who underwent surgical treatment with or without lym-
phadenectomy at our center.
PATIENTS AND METHODS
This retrospective study examined patients with endometrial
cancer who underwent surgical treatment at the Tokushima
University Hospital during 2000

2011. Informed consent for the
treatment to be carried out had been given.
We identified 241 patients were treated via hysterectomy and
removal of the existing adnexal structures, and had no other malig-
nancy that was diagnosed within 5 years before or after the diagnosis
of endometrial cancer. Among these 241 patients, 188 patients
fulfilled our eligibility criteria : (i) magnetic resonance imaging-
and computed tomography had confirmed the tumor was con-
fined to the uterine corpus (except for occult positive lymph nodes,
positive peritoneal cytology results, or both) and (ii) had not under-
gone preoperative therapy. Among the 188 included patients, 39
patients had only undergone hysterectomy and 149 patients had
undergone hysterectomy with systematic lymphadenectomy.
In all cases, the uterus was bisected along the lateral uterine
walls, and pathologists used frozen slides to determine the histo-
logical subtype, grade, and depth of myometrial invasion. Pelvic
lymphadenectomy was typically performed, and para-aortic lym-
phadenectomy was added for patients with50% myometrial inva-
sion and/or a grade 3 tumor. Among patients who underwent sur-
gery after 2004, the lymphadenectomy was omitted for patients
with minor (5 mm) of myometrial invasion and a grade 1 tumor.
Staging was defined based on the FIGO surgical staging system
[Pecorelli, 2009], and the architectural grading was based on the
degree of glandular differentiation [Creasman, 1989]. After the pri-
mary operation, some patients received adjuvant chemotherapy due
to their risk of recurrence (e.g., a grade 3 tumor,50% myometrial
invasion, cervical invasion, extrauterine invasion, or positive lymph
nodes). Patients who were unavailable for follow-up were not in-
cluded in the analyses of survival and recurrence.
For our analyses, we extracted the tumors’ characteristics from
the original pathology reports. All hematoxylin and eosin-stained
slides from the primary tumor were also retrospectively reviewed
to confirm the original diagnosis of adenocarcinoma and to deter-
mine the FIGO grade, histological subtype, and presence of LVSI.
We classified the LVSI into four categories : L0, no lymphatic and
vascular invasion ; L1, a single lymphatic or vascular invasion on
the slide ; L2, multiple lymphatic or vascular invasions on the slide
that did not fulfil the L3 criterion ; and L3, multiple lymphatic or
vascular invasions in each microscopic view (100× magnification).
ORIGINAL
Can systematic lymphadenectomy be omitted for low-risk
endometrial cancer?
Kanako Yoshida1), Masato Nishimura1), Akiko Abe1), Takeshi Kato1), Hiroyuki Furumoto2), and Minoru Irahara1)
1)Tokushima University Hospital, Tokushima, Japan, 2)Tokushima Municipal Hospital, Tokushima, Japan
Abstract : The objective of this study was to identify pathological indicators that could be used to identify a
subgroup of patients with apparent stage I endometrial cancer who do require retroperitoneal lymphadenec-
tomy. 188 T1 endometrial cancer patients underwent primary surgery at Tokushima University Hospital. We
retrospectively evaluated their clinical records and histopathological factors. Systematic lymphadenectomy was
performed for 149 patients, and 39 patients (grade 1 with 5 mm of myometrial invasion) were treated without
lymphadenectomy. Lymph node metastases were found in 19 (12.8%) of the lymphadenectomy cases. Twenty-four
patients with a T1a endometrium-limited lesion did not exhibit lymph node metastasis. Three (3.1%) of the 95
patients with a T1a lesion exhibited lymph node metastasis, and these 3 cases exhibited approximately 50%
myometrial invasion. The 39 low-risk patients who did not undergo systematic lymphadenectomy remain alive
without recurrence. Systematic lymphadenectomy could be omitted for patients with a grade 1 tumor and minor
myometrial invasion of less than 5mm. J. Med. Invest. 65 : 221-224, August, 2018
Keywords : Endometrial cancer, low-risk, lymphadenectomy
Received for publication April 25, 2018 ; accepted June 10, 2018.
Address correspondence and reprint requests to Kanako Yoshida,
Department of Obstetrics & Gynecology, Tokushima University Hospital,
3 -18 -15, Kuramoto, Tokushima 770-8503, Japan and Fax : +81-88 -631-
2630.
The Journal of Medical Investigation Vol. 65 2018
221
RESULTS
Based on the 2008 FIGO criteria, we included 150 patients with
stagedisease, 6 patients with stagedisease, and 32 patients with
stagedisease. Among 188 T1 endometrial cancer patients, 38
cases had extrauterine lesions, therefore they were diagnosed as
stageor stage(Table 1). As shown in Table 2, pelvic and aortic
node metastases were found in 19 (12.8%) of the 149 patients who
underwent hysterectomy with systematic lymphadenectomy. Sixteen
(29.6%) of the 54 patients with a T1b lesion exhibited pelvic lymph
node metastasis (Table 2a). The lymph node-positive rate among
cases with grade 2 tumors was 10.5% (4/38). Twenty- four patients
with a T1a endometrium-limited lesion did not exhibit lymph node
metastasis, whereas 1 of 19 T1a myometrial invasion cases exhib-
ited lymph node metastasis (Table 2b). Table 2c shows that the
patients with50% myometrial invasion, a grade 1 tumor, and no
LVSI did not have lymph node metastases (0/50). In patients
with25% myometrian invasion, lymph node metastasis was not
detected even though LVSI was observed. Three patients (3.1%)
among the 95 patients with a T1a lesion exhibited lymph node me-
tastasis, and these 3 patients all exhibited LVSI and approximately
50% myometrial invasion (Table 2b, Table 3). The 39 patients who
did not undergo systematic lymphadenectomy are alive and with-
out recurrence (Table 4).
Table 1. T1 patients’ clinical characteristics
Lymphadenectomy
(n=149)
No lymphadenectomy
(n=39)
Total
(n=188)
Median age 58 (24-89) 60 (42-86) 59 (24-89)
FIGO stage, No. (%)
A (EM only) 21 (14.1) 14 (35.9) 35 (18.6)
A (EM) 64 (43.0) 23 (59.0) 87 (46.3)
B 28 (18.8) 0 28 (14.9)
A 2 (1.3) 0 2 (1.0)
B 4 (2.7) 0 4 (2.1)
A 9 (6.0) 2 (5.1) 11 (5.9)
B 1 (0.6) 0 1 (0.5)
C 20 (13.4) 0 20 (10.6)
4 0 0 0
Tumor histotype, grade
Endometrioid
Endometrioid G1 80 (53.7) 37 (94.9) 117 (62.2)
G2 35 (23.5) 0 35 (18.6)
G3 10 (6.7) 0 10 (5.3)
Adenosquamous G1 4 (2.7) 1 (2.6) 5 (2.7)
G2 0 0 0
G3 1 (0.6) 0 1 (0.5)
Adenoacantoma G1 7 (4.7) 1 (2.6) 8 (4.3)
G2 3 (2) 0 3 (1.6)
G3 0 0 0
Serous 5 (3.4) 0 5 (2.7)
Clear cell 3 (2) 0 3 (1.6)
Mixed cell 1 (0.6) 0 1 (0.5)
EM : endometrium
Table 2-a. Myometrial invasion and Lymph node positivity of T1
patients
Myometrial
invasion (%)
Pelvic LN
Positivity (%)
Para-aortic LN
positivity (%)
Pelvic and para-aortic LN
positivity (%)
25 0/57 (0) 0/7 (0) 0/57 (0)
25-50 2/38 (5.2) 1/5 (20) 3/38 (7.9)
50 -75 5/16 (31.2) 0/5 (0) 5/16 (31.2)
75 11/38 (28.9) 4/25 (16) 11/38 (28.9)
Total 18/149 (12.1) 5/42 (11.9) 19/149 (12.8)
LN : lymph node
Table 2-b. Histopathologic factors on lymph node metastasis of 149 T1
patients
LN positivity
(%) T Lymph -vascular space invasion
Endometrioid
grade1 8/91 (8.8) T1a (EM only) 0/16
T1a (EM) 1/48
T1b 7/27
L0 : 0/16
L0 : 0/34 L1 : 0/12 L2 : 1/2
L0 : 2/15 L1 : 4/9 L2 : 0/1 L3 : 1/2
grade2 4/38 (10.5) T1a (EM only) 0/5
T1a (EM) 1/19
T1b 3/14
L0 : 0/5
L0 : 0/10 L1 : 1/6 L2 : 0/3
L0 : 0/2 L1 : 2/7 L2 : 1/3 L3 : 0/2
grade3 4/11 (36.4) T1a (EM only) 0/0
T1a (EM) 1/3
T1b 3/8
L1 : 1/2 unknown : 0/1
L0 : 0/2 L1 : 0/2 L3 : 3/4
Serous
Clear cell
Mixed cell
3/9 (33.3) T1a (EM only) 0/3
T1a (EM) 0/1
T1b 3/5
L0 : 0/3
L0 : 0/1
L0 : 1/2 L1 : 1/1 L2 : 1/1 L3 : 0/1
Total 19/149 (12.8)
LN : lymph node
EM : endometrium
Table 2-c. Histopathologic factors on lymph node metastasis of T1
grade1 patients
Myometrial
invasion (%) LN positivity (%)
Lymphvascular
space invasion
25 0/41 (0)
L0 : 0/36
L1 : 0/4
L2 : 0/1
L3 : 0
25-50 1/23 (4.3)
L0 : 0/14
L1 : 0/8
L2 : 1/1
L3 : 0
50-75 3/9 (33.3)
L0 : 0/6
L1 : 2/2
L2 : 0
L3 : 1/1
75 4/18 (22.2)
L0 : 2/9
L1 : 2/7
L2 : 0/1
L3 : 0/1
Total 8/91 (8.8)
LN : lymph node
222 K. Yoshida, et al. Lymphadenectomy for endometrial cancer
DISCUSSION
Trimble et al. investigated the effect of pelvic lymph node sam-
pling on survival among women with FIGO stageendometrial
cancer, and reported that it increased survival among patients with
stage I disease and a grade 3 tumor, but not among patients with
grade 12 tumors [Trimble, 1998]. Cragun et al. have also reported
that the removal of11 pelvic lymph nodes improved overall sur-
vival and progression-free survival among patients with poorly
differentiated tumors in apparent early -stage endometrial cancer
[Cragun, 2005]. However, several other reports have described no
significant differences in survival and recurrence among patients
with stage I endometrial cancer who did and did not undergo lym-
phadenectomy [Bar, 1998 ; Candiani, 1990]. Furthermore, two
randomized studies have reported no significant benefits in overall
or recurrence- free survival after pelvic lymphadenectomy among
patients with early endometrial cancer [ASTEC study group, 2009 ;
Benedetti, 2008]. Onda et al. have reported that aortic and pelvic
lymphadenectomy followed by adjuvant chemotherapy and radio-
therapy improved survival among patients with positive aortic
lymph nodes [Onda, 1997]. Thus, Chan et al. have suggested that
the extent of lymph node dissection affects survival among women
with intermediate/high-risk endometrioid uterine cancer, but not
among low-risk patients [Chan, 2006].
Several authors have demonstrated that primary tumor diame-
ter and lymphatic or vascular invasion significantly affect progno-
sis, and that the following factors are significant predictors of a poor
prognosis :50% myometrial invasion, non-endometrioid histol-
ogy, lymphovascular invasion, absence of associated hyperplasia,
and a tumor diameter of2 cm [Mariani et al., 2000 ; Mariani et al.,
2008]. Furthermore, those authors have reported that lymphadenec-
tomy can be omitted for patient with disease that is confined to the
uterus, histological grade 12, a tumor diameter of2 cm,50%
myometrial invasion, and no metastasis [Mariani et al., 2000 ;
Mariani et al., 2008]. LVSI has also been reported as a risk factor in
endometrial cancer, and para-aortic lymph node metastasis is sig-
nificantly affected by histological type, tumor grade, depth of
myometrial invasion, cervical invasion, LVSI, serosal/adnexal in-
vasion, and pelvic lymph node metastasis [Chang, 2011 ; Karube,
2010].
Interestingly, 37.8% of patients who undergo lymphadenectomy
experience postoperative lymphedema [Todo, 2010], which may
indicate that pelvic lymphadenectomy and para-aortic lymphadenec-
tomy are excessive in low-risk cases of endometrial cancer. In the
Table 3. Characteristics of patients with lymph node metastasis
Case Age Histotype T Myometrialinvasion (%) PLN meta PAN meta Outcome
1 54 Endomettrioid G2,L2 T1b 53 +  9Y NED
2 64 Adeniacantoma G1,L2 T1a 45 + ND 8Y NED
3 51 Endometrioid G3,L3 T1b 86 + + 7Y7M NED
4 46 Endometrioid G2,L1 T1a 45 + ND 7Y7M NED
5 65 Endomettrioid G1,L1 T1b 96 +  7Y1M NED
6 57 Endomettrioid G2L1 T1b 97 +  6Y6M NED
7 68 Endomettrioid G1,L0 T1b 93 + ND 6Y2M NED
8 79 Clear cell ,L1 T1b 79 + ND 5Y10M NED
9 66 Endomettrioid G3,L3 T1b 99 +  1Y2M DOD
10 52 Endomettrioid G2,L1 T1b 100 + + 5Y8M NED
11 72 Endomettrioid G3,L3 T1b 100 + + 5Y8M NED
12 53 Endomettrioid G1,L1 T1b 67 + ND 5Y1M NED
13 68 Endomettrioid G1,L1 T1b 75 +  2Y5M DOD
14 65 Endomettrioid G1,L0 T1b 76 + ND 4Y NED
15 73 Endometrioid G3,L1 T1a 50  + 2Y11M AWD
16 67 Serous, L2 T1b 98 + + 2M10M NED
17 69 Clear cell,L0 T1b 71 + ND 2Y DOD
18 41 Endomettrioid G1,L3 T1b 60 +  3Y4M NED
19 69 Endomettrioid G1,L0 T1b 78 +  2Y7M NED
PLN : pelvic lymph node
PAN : para-aortic lymph node
ND : not done
NED : no evidence of disease
AWD : alive with disease
DOD : died of disease
Table 4. Metastatic site after operation for patients who did or did not
lymphadenectomy
Metastatic site Lymphadenectomy(n=149)
No lymphadenectomy
(n=39)
Median follow up time
(months) 62 (22-138) 52 (22-145)
No metastasis No. (%) 140 (94) 39 (100)
Metastasis No. (%) 9 (6) 0
Lymph node 3 0
Lung 2 0
Intraperitoneum 3 0
Vagina 1 0
Bone 1 0
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present study, we found that 3 patients with a T1a lesion exhibited
lymph node metastasis, and all 3 patients also exhibited approxi-
mately 50% myometrial invasion and LVSI. In contrast, we did not
observe lymph node metastasis in patients with T1a lesions and
25% myometrial invasion, a grade 1 tumor, and the absence of LVSI.
Moreover, 9 (6%) of the 149 patients who underwent lymph node
dissection experienced recurrence, and the cases with recurrence
exhibited approximately 50% myometrial invasion. Thus, it is neces-
sary to carefully select low-risk cases when we omit the lymph
node dissection, as the pelvic lymph nodes are the most common
site of extrauterine metastasis from endometrial cancer at the in-
itial presentation. In our institution, the pathologists diagnose the
histological subtype, grade, and depth of the myometrial invasion
using frozen sections during surgery, and then we determine
whether lymphadenectomy is appropriate (we omit it in cases of
grade 1 endometrioid adenocarcinoma with minor myometrial
invasion of less than 5 mm). Based on this approach, we did not
observe recurrence in the 39 cases that did not undergo lym-
phadenectomy, which may indicate that our criteria for omitting
systematic lymphadenectomy are appropriate. However, it may be
difficult to pathologically diagnose LVSI during the surgery, due to
the limited number of slides. Furthermore, we observed that 1
patient with a T1a/grade 1 tumor exhibited lymph node metastasis
and LVSI. Therefore, if moderate myometrial invasion or LSIV are
found after the surgery, it may be appropriate to consider additional
treatment. Nevertheless, it may be possible to omit lymph node
dissection in cases with slight myometrial invasion, and even in
cases with a grade 2 tumor. For example, given that lymph node
metastasis was only observed in 1 of the 24 stage IA cases, lymph
node dissection might be omitted in cases with minor myometrial
invasion, even if it is difficult to differentiate between grade 1 and 2
tumors during the surgery.
CONCLUSION
Patients with stage IA endometrial cancer and a grade 1 tumor
with minor myometrial invasion could be treated without retro-
peritoneal lymphadenectomy. However, retroperitoneal lymph
node dissection should be performed as usual if the patient is
considered high-risk. Moreover, we recommend performing a
larger prospective randomized controlled study to identify histopa-
thological factors that could be used to indicate the omission of
selective lymphadenectomy.
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